Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Total Long Term Debt: 2009-2012

  • Madrigal Pharmaceuticals' Total Long Term Debt fell 94.12% to $100,000 in Q4 2012 from the same period last year, while for Dec 2012 it was $100,000, marking a year-over-year decrease of 94.12%. This contributed to the annual value of $100,000 for FY2012, which is 94.12% down from last year.
  • According to the latest figures from Q4 2012, Madrigal Pharmaceuticals' Total Long Term Debt is $100,000, which was down 94.12% from $1.7 million recorded in Q4 2011.
  • In the past 5 years, Madrigal Pharmaceuticals' Total Long Term Debt ranged from a high of $3.6 million in Q4 2009 and a low of $100,000 during Q4 2012.
  • In the last 3 years, Madrigal Pharmaceuticals' Total Long Term Debt had a median value of $1.7 million in 2011 and averaged $1.2 million.
  • Data for Madrigal Pharmaceuticals' Total Long Term Debt shows a maximum YoY tumbled of 94.12% (in 2012) over the last 5 years.
  • Quarterly analysis of 4 years shows Madrigal Pharmaceuticals' Total Long Term Debt stood at $3.6 million in 2009, then plummeted by 50.00% to $1.8 million in 2010, then fell by 5.56% to $1.7 million in 2011, then crashed by 94.12% to $100,000 in 2012.
  • Its last three reported values are $100,000 in Q4 2012, $1.7 million for Q4 2011, and $1.8 million during Q4 2010.